67267-08-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 2,5-dihydro-5-oxo-1-phenyl-1H-1,2,4-triazole-3-carboxylate is used as an intermediate in the synthesis of pharmaceuticals for its ability to modulate biological systems. Its unique structure allows it to be a key component in creating new drugs with specific therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Ethyl 2,5-dihydro-5-oxo-1-phenyl-1H-1,2,4-triazole-3-carboxylate is utilized as a research compound to explore its potential interactions with biological targets. This can lead to the discovery of new drug candidates and therapeutic agents.
Used in Drug Development:
Ethyl 2,5-dihydro-5-oxo-1-phenyl-1H-1,2,4-triazole-3-carboxylate is used in drug development as a building block for creating novel molecules with potential therapeutic applications. Its structural features make it a versatile component in the design of new pharmaceuticals.

InChI:InChI=1/C11H11N3O3/c1-2-17-10(15)9-12-11(16)14(13-9)8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H,12,13,16)

Upstream product

• 100-63-0 phenylhydrazine 
• 28663-68-5 ethyl (phenylhydrazono)chloroacetate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 36999-43-6 ethyl α-amino-α-(phenylhydrazono)glyoxylate 
• 1105634-63-6 ethyl 2-amino-2-(phenylhydrazono)acetate 
• 62-53-3 aniline 
• 2295-31-0 thiazoline-2,4-dione 

Relevant academic research and scientific papers

Monoacylglycerol Lipase Modulators

Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.

The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype

In this work, we describe the identification of the 1,2,4-triazolo[4,3-a]pyrazin-3-one as a new versatile scaffold for the development of adenosine human (h) receptor antagonists. The new chemotype ensued from a molecular simplification approach applied to our previously reported 1,2,4-triazolo[4,3-a]quinoxalin-1-one series. Hence, a set of novel 8-amino-2-aryl-1,2,4-triazolopyrazin-3-one derivatives, featured by different substituents on the 2-phenyl ring (R) and at position 6 (R6), was synthesized with the main purpose of targeting the hA2A adenosine receptor (AR). Several compounds possessed nanomolar affinity for the hA2A AR (Ki = 2.9-10 nM) and some, very interestingly, also showed high selectivity for the target. One selected potent hA2A AR antagonist (12, R = H, R6 = 4-methoxyphenyl) demonstrated some ability to counteract MPP+-induced neurotoxicity in cultured human neuroblastoma SH-SY5Y cells, a widely used in vitro Parkinson's disease model. Docking studies at hAR structures were performed to rationalize the observed affinity data.

A new method for the synthesis of 1-aryl-1,2,4-triazole derivatives

A new and convenient one-step recyclization method for the synthesis of ethyl 1-aryl-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxylates is reported. Various ethyl chloro(2-arylhydrazinylidene)ethanoates react with thiazolidine-2,4-dione in the presence of potassium hydroxide to produce the 1-aryl-1,2,4-triazole derivatives in moderate to good yields. The procedure is economical, environmentally friendly and simple to perform. Georg Thieme Verlag Stuttgart - New York.